Subscribe
shutterstock_1113551483_sharafmaksumov
sharafmaksumov / Shutterstock.com
11 February 2020Big PharmaRory O'Neill

Clarivate’s ‘drugs to watch’ list signals high prices to come

Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.

More on this story

Americas
FDA, FTC send message to biologics makers at competition workshop
10 March 2020   US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Generics
Campaigners ask US govt to force down prices for common drugs
24 March 2022   Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility